Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
AchilleS tendinoPathy treated with cortIcosteRoid injEctions.
Disc Medicine
Achilles tendinopathy
1 trial -
A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI
Wuhan Createrna Science and Technology Co., Ltd
Primary Immune Thrombocytopenia
1 trial -
Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10
The George Institute
Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib
1 trial -
IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.
Disc Medicine
Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract
1 trial -
IVERMECTIN
The George Institute
Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.
1 trial -
corticosteroids
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Severe Colitis (ASC)
1 trial -
corticosteroids combined with immunoglobulin and romiplostim
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Immune Thrombocytopenia
1 trial -
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
AstraZeneca AB
Asthma
1 trial -
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
Lacuna Pharma Pty Ltd
Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.
1 trial -
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
Lacuna Pharma Pty Ltd
inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.
1 trial -
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroids
Cassiopea S.p.A.
Test of vasocontriction properties for classification of topical steroid potency
1 trial -
Daratumumab and corticosteroid treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acquired Hemophilia
1 trial -
Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Allergic Rhinitis
1 trial -
The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.
Pierre Fabre Australia Pty Ltd
Chronic Obstructive Pulmonary Disease
1 trial -
rituximab combined with corticosteroids
The First People's Hospital of Lianyungang
Primary Membranous Nephropathy
1 trial -
Corticosteroid
Beijing Anzhen Hospital
Heart Valve Diseases
1 trial -
Corticosteroid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Heart Valve Diseases
1 trial -
Corticosteroid
United Therapeutics Europe Ltd
Chronic Low Back Pain
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources